Sugi Predict

Sugi Predict / Compounds / SCHEMBL1808673

SCHEMBL1808673

SCHEMBL1808673

CCOC(=O)c1ncc(OC)s1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.44
▸ ALDH1A1 P00352 3/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ GAA P10253 2/20 0.44
▸ HPGD P15428 1/20 0.44
▸ HSD17B10 Q99714 3/20 0.43
▸ CDC7 O00311 3/20 0.43
▸ DBF4 Q9UBU7 3/20 0.43
▸ FHIT P49789 1/20 0.41
▸ DPP4 P27487 2/20 0.40
▸ GABRP O00591 1/20 0.40
▸ GABRD O14764 1/20 0.40
▸ GABRA1 P14867 1/20 0.40
▸ GABRB1 P18505 1/20 0.40
▸ GABRG2 P18507 1/20 0.40
▸ GABRB3 P28472 1/20 0.40
▸ GABRA5 P31644 1/20 0.40
▸ GABRA3 P34903 1/20 0.40
▸ GABRA2 P47869 1/20 0.40
▸ GABRB2 P47870 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL128677 0.80 CDC7 (0.46) MAPTALDH1A1SMN1; SMN2GAAHPGD
SCHEMBL16933028 0.79 CDC7 (0.60) MAPTALDH1A1SMN1; SMN2GAAHPGD
SCHEMBL128676 0.77 CDC7 (0.48) MAPTALDH1A1SMN1; SMN2GAAHPGD
SCHEMBL10272646 0.77 ALDH1A1 (0.46) MAPTALDH1A1SMN1; SMN2GAAHPGD
SCHEMBL1641657 0.77 CDC7 (0.44) MAPTALDH1A1SMN1; SMN2GAAHPGD
SCHEMBL5879520 0.77 ALDH1A1 (0.50) MAPTALDH1A1SMN1; SMN2GAAHPGD
SCHEMBL528192 0.76 HCAR2 (0.55) MAPTALDH1A1SMN1; SMN2GAAHPGD
SCHEMBL5326662 0.76 SMN1; SMN2 (0.46) MAPTALDH1A1SMN1; SMN2GAAHPGD
SCHEMBL18606113 0.76 CDC7 (0.50) MAPTALDH1A1SMN1; SMN2GAAHPGD
SCHEMBL1810774 0.76 SIRT6 (0.40) MAPTKDM4EMAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3885340-B1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2024-11-27 — — EP disclosed
EP-3885340-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2021-09-29 — — EP disclosed
US-11046713-B2 Androgen receptor modulating compounds ORION CORPORATION (FI) 2021-06-29 — — US disclosed
EP-3369732-B1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2021-05-26 — — EP disclosed
US-20200299307-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2020-09-24 — — US disclosed
US-10711013-B2 Androgen receptor modulating compounds ORION CORPORATION (FI) 2020-07-14 — — US disclosed
US-20190100536-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2019-04-04 — — US disclosed
US-10118933-B2 Androgen receptor modulating compounds ORION CORPORATION (FI) 2018-11-06 — — US disclosed
EP-3369732-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2018-09-05 — — EP disclosed
EP-3262035-A1 ALKYNYL ALCOHOLS AND METHODS OF USE F. Hoffmann-La Roche AG (CH) 2018-01-03 — — EP disclosed
WO-2016135163-A1 ALKYNYL ALCOHOLS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2016-09-01 — — WO disclosed
WO-2016135163-A1 ALKYNYL ALCOHOLS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2016-09-01 — — WO disclosed
EP-3056485-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS Orion Corporation (FI) 2016-08-17 — — EP disclosed
US-20150203479-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION 2015-07-23 — — US disclosed
US-8975254-B2 Androgen receptor modulating compounds ORION CORPORATION (FI) 2015-03-10 — — US disclosed
EP-2493858-B1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORP (FI) 2014-07-02 — — EP disclosed
US-20120225867-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2012-09-06 — — US disclosed
EP-2493858-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS Orion Corporation (FI) 2012-09-05 — — EP disclosed
WO-2011051540-A9 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2012-06-21 — — WO disclosed
WO-2011051540-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS ORION CORPORATION (FI) 2011-05-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10118933-B2 Androgen receptor modulating compounds AR, NR5A1, SHBG MAPT 3306/4885ALDH1A1 570/4885SMN1; SMN2 3609/4885
US-10711013-B2 Androgen receptor modulating compounds AR, NR5A1, SHBG MAPT 3306/4885ALDH1A1 570/4885SMN1; SMN2 3609/4885
US-20200299307-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS AR, NR5A1, SHBG MAPT 3306/4885ALDH1A1 570/4885SMN1; SMN2 3609/4885
US-20190100536-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS AR, NR5A1, SHBG MAPT 3306/4885ALDH1A1 570/4885SMN1; SMN2 3609/4885
US-11046713-B2 Androgen receptor modulating compounds AR, NR5A1, SHBG MAPT 3306/4885ALDH1A1 570/4885SMN1; SMN2 3609/4885
US-20150203479-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS AR, NR5A1, SHBG MAPT 3306/4885ALDH1A1 570/4885SMN1; SMN2 3609/4885
US-20120225867-A1 ANDROGEN RECEPTOR MODULATING COMPOUNDS AR, NR5A1, SHBG MAPT 3306/4885ALDH1A1 570/4885SMN1; SMN2 3609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.